Ranbaxy family faces huge tax outgoing in deal with Daiichi Sankyo
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratories' founding family faces the prospect of paying significant capital gains taxes after the Securities and Exchange Board of India (SEBI) rejected the company's plans to complete its sale of the company to Daiichi Sankyothrough a "block deal" on the bourses.
You may also be interested in...
Biocon Biologics CEO Makes Surprise Exit
The CEO of Biocon’s biosimilars subsidiary has unexpectedly departed the role. Management stresses there is no disruption to its "strategic intent", but COVID-19 has "dampened" the arm’s push to reach its aspirational $1bn revenue target by 2022.
Prices Plunge As Xarelto Generics Arrive In India
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.
Dr Reddy’s Wants To Break Into Top Five In India
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
Need a specific report? 1000+ reports available
Buy Reports